title: Therapeutic effect of CNP on renal osteodystrophy by antagonizing the FGF-23/MAPK pathway.
abstract: Renal osteodystrophy (ROD) is highly prevalent in chronic kidney disease (CKD). Because most patients with ROD are asymptomatic in the early stage and bone biopsy remains not a routine procedure in many clinical settings; therefore, several biochemical parameters may help to identify the existence of ROD. C-type natriuretic peptide (CNP) is considered as a positive regulator of bone formation. Both urinary excretion and renal expression of CNP are markedly up-regulated in the early stages of CKD, whereas they are still progressively declined accompanied by CKD progression, which invites speculation that the progressive decline of CNP may contribute, in part, to the pathogenesis of ROD. In addition, fibroblast growth factor (FGF)-23 is a bone-derived endocrine regulator of phosphate homeostasis. The elevation of serum FGF-23 has been recognized as a common feature in CKD to maintain normophosphatemia at the expense of declining 1,25-dihydroxyvitamin D values. Since the effects of CNP and FGF-23 on bone formation appear to oppose each other, it is reasonable to propose a direct interaction of their signaling pathways during the progression of ROD. CNP and FGF-23 act through a close or reciprocal pathway and are in agreement with recent studies demonstrating a down-regulatory role of the mitogen-activated protein kinase activity by CNP. The specific node may act at the level of RAF-1 through the activation of cyclic guanosine monophosphate-dependent protein kinases II.
authors.affiliation: a Department of Pediatrics , The First Affiliated Hospital of Anhui Medical University , Hefei , People's Republic of China .
authors.forename: Peng
authors.initials: P
authors.lastname: Hu
authors.affiliation: a Department of Pediatrics , The First Affiliated Hospital of Anhui Medical University , Hefei , People's Republic of China .
authors.forename: Bao Yu
authors.initials: BY
authors.lastname: Huang
authors.affiliation: a Department of Pediatrics , The First Affiliated Hospital of Anhui Medical University , Hefei , People's Republic of China .
authors.forename: Xun
authors.initials: X
authors.lastname: Xia
authors.affiliation: b Department of Urology , Anhui Provincial Hospital Affiliated Anhui Medical University , Hefei , People's Republic of China , and.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Xuan
authors.affiliation: a Department of Pediatrics , The First Affiliated Hospital of Anhui Medical University , Hefei , People's Republic of China .
authors.forename: Bo
authors.initials: B
authors.lastname: Hu
authors.affiliation: c Department of Pediatrics , The First Affiliated Hospital of Guangxi Medical University , Nanning , People's Republic of China.
authors.forename: Yuan Han
authors.initials: YH
authors.lastname: Qin
mesh_terms: D016723:Bone Remodeling / Q000235:genetics; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000150:complications / Q000235:genetics* / Q000473:pathology; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000235:genetics*; D006801:Humans; D020929:Mitogen-Activated Protein Kinase Kinases / Q000235:genetics / Q000378:metabolism; D020098:Natriuretic Peptide, C-Type / Q000235:genetics* / Q000378:metabolism; D019908:Proto-Oncogene Proteins c-raf / Q000235:genetics; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000235:genetics* / Q000473:pathology; D015398:Signal Transduction / Q000235:genetics; D014807:Vitamin D / Q000031:analogs & derivatives / Q000097:blood
chemical_list: C000717427:FGF23 protein, human; D020098:Natriuretic Peptide, C-Type; D014807:Vitamin D; D005346:Fibroblast Growth Factors; C097949:1,25-dihydroxyvitamin D; D000089703:Fibroblast Growth Factor-23; D019908:Proto-Oncogene Proteins c-raf; D020929:Mitogen-Activated Protein Kinase Kinases
keywords: Bone remoding; C-type natriuretic peptide; chronic kidney disease; fibroblast growth factor-23; mitogen-activated protein kinase